NR1H4 and cancer: In this study, we investigated, using both in vitro and in vivo experimental models, the ability of the synthetic FXR agonist GW4064 to interfere with cancer-promoting activities of CAFs focusing on the possible opposing role of activated FXR on leptin-induced breast tumor growth and progression.